ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2983

The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study

Nathalie Carrier1, Sophie Roux2, Ariel Masetto2, Artur J deBrum Fernandes3, Patrick Liang4, Meryem Maoui5 and Gilles Boire4, 1Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 2Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 3Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 4Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 5Bristol-Myers Squibb Canada., St-Laurent, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Anti-CCP antibodies and rheumatoid arthritis (RA), Disease Activity, Genetic Biomarkers, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: To analyze the evolution of baseline demographic, clinical, serological and genetic characteristics of patients with incident RA over 20 years.

Methods: Since July 1998, the Early Undifferentiated PolyArthritis (EUPA) cohort recruits consecutive adults with recent-onset immune-mediated synovitis affecting at least 3 joints. Baseline characteristics were compared in three subgroups of patients fulfilling RA criteria according to date of inclusion (1998-2004; 2005-2010; 2011-2017). Anti-cyclic citrullinated peptide (CCP2) antibodies and RF were measured using commercial assays, while anti-Sa were measured with an in-house assay or a commercial assay calibrated with it (Arthritis Rheum;2009;60:698-707). Human Leucocyte Antigen (HLA)-DR alleles were determined using sequence-specific primer PCR. False discovery rate correction was used to adjust p-values for multiple comparisons.

Results: 739 patients were included: 247 in 1998-2004; 263 in 2005-2010; 229 in 2011-2017. We observed a decrease in current smokers over time: 22.4, 18.6, 12.3%, respectively (p=0.04). Symptom duration increased (2.8, 3.5, 4.1 months; p<0.001). Markers of inflammation decreased (ESR (mm/h): 36, 26, 24, p=0.01; CRP (mg/L): 15.0, 11, 8.9, p=0.002), as did disease activity (DAS28-CRP: 5.5, 5.1, 5.0, p=0.01), and patient overall assessment of disease activity (PGA) (59.0, 56.5, 49.0 mm, p=0.02); without a parallel decrease in joint counts (SJC: 11, 11, 12 NS) or an increase in corticosteroid or DMARD use before inclusion (33.6, 50.2, 36.7%, p=0.002, 26.7, 39.5, 28.8%, p=0.01, respectively).

RF positivity decreased (47.8, 36.9, 36.7%, p=0.03), but positivity remained stable for anti-Sa (22.9, 18.0, 22.5% NS) and anti-CCP2 (40.8, 35, 35.4% NS), although the mean titers of anti-CCP2 significantly decreased (3.5, 3.2 and 1.0 IU/ml, p<0.001). The proportion of Shared epitope (SE) positive patients decreased significantly (51.0, 42, 35.2%; p=0.04), while the DERAA epitope remained stable.

Relative to anti-CCP negatives, the proportion of SE (62.2 vs 33.8%, RR=2.01, p<0.001) and current smokers (21.8 vs 15.5%, RR=1.28, p=0.04) were higher among anti-CCP2+ patients, and remained stable in anti-CCP2+ patients over time (64.9, 61.8, 54.3%, NS; 25.3, 20.9, 18.8% NS respectively). SE positivity and current smoking decreased in anti-CCP2- patients (41.7, 30.3, 22.6%, p=0.02; 20.6, 17.2, 8.6%, p=0.02).

Conclusion: In this cohort of recent onset RA recruited over 20 years, we observed a constant drift towards less inflammatory RF-negative arthritis at baseline. Decreasing smoking rates paralleled lower levels but not lower incidence of positive CCP. The increasing proportion of SE negative patients in this RA cohort with a relatively stable incidence over 20 years suggest the implication of as yet unidentified environmental arthritis-inducing factors acting on this aging population.


Disclosure: N. Carrier, None; S. Roux, None; A. Masetto, None; A. J. D. Fernandes, None; P. Liang, None; M. Maoui, Bristol-Myers Squibb, 3; G. Boire, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Carrier N, Roux S, Masetto A, Fernandes AJD, Liang P, Maoui M, Boire G. The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-changing-faces-of-rheumatoid-arthritis-patients-at-presentation-a-20-year-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-changing-faces-of-rheumatoid-arthritis-patients-at-presentation-a-20-year-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology